Caxton Associates LLP Innoviva, Inc. Transaction History
Caxton Associates LLP
- $4.11 Billion
- Q3 2025
A detailed history of Caxton Associates LLP transactions in Innoviva, Inc. stock. As of the latest transaction made, Caxton Associates LLP holds 28,033 shares of INVA stock, worth $623,734. This represents 0.01% of its overall portfolio holdings.
Number of Shares
28,033
Previous 18,723
49.72%
Holding current value
$623,734
Previous $376 Million
99.86%
% of portfolio
0.01%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding INVA
# of Institutions
281Shares Held
82.7MCall Options Held
13.2KPut Options Held
156K-
Black Rock Inc. New York, NY9.63MShares$214 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.1MShares$158 Million0.0% of portfolio
-
Putnam Investments LLC Boston, MA6.27MShares$140 Million0.14% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny4.59MShares$102 Million0.12% of portfolio
-
Dimensional Fund Advisors LP Austin, TX4.33MShares$96.4 Million0.02% of portfolio
About Innoviva, Inc.
- Ticker INVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 69,706,000
- Market Cap $1.55B
- Description
- Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...